Beam Therapeutics Inc (BEAM) support and resistance · rev $63.5M
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
This page maps Beam Therapeutics Inc (BEAM) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported BEAM revenue for 2024-12-31 was $63.5M. Net income was -$376.7M. Revenue was down 83.2% from 2023-12-31 to 2024-12-31. BEAM currently screens at market cap $2.01B.
BEAM currently screens at market cap $2.01B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new BEAM 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the BEAM quote page for the session range and the stock page for the full model.
Not investment advice.